Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Apyx Medical Corporation - Common Stock (NQ: APYX ) 1.640 +0.040 (+2.50%) Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Apyx Medical Corporation - Common Stock < Previous 1 2 3 4 Next > Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures August 08, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook August 08, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024 July 25, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook May 09, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corp. (NASDAQ: APYX) Leading the Way in Friday Trading Based on Percentage Gain May 12, 2023 Via Investor Brand Network Apyx Medical Corporation Announces Board Leadership Transition May 09, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024 April 25, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit April 11, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook March 21, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024 March 04, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting February 21, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body January 22, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results January 08, 2024 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer November 28, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors November 09, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook November 09, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November November 07, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023 October 02, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook August 10, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2023 Financial Results on August 10, 2023 June 29, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Announces FDA 510(k) Clearance for the Renuvion® Micro Handpiece June 14, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook May 11, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring April 28, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation to Release First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023 April 05, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook March 16, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissue, Where Needed February 27, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial February 21, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2022 Financial Results on March 16, 2023 February 16, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of the Renuvion® APR Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction February 01, 2023 From Apyx Medical Corporation Via Business Wire Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results January 10, 2023 From Apyx Medical Corporation Via Business Wire < Previous 1 2 3 4 Next > Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
